Silencing IL-13Rα2 Promotes Glioblastoma Cell Death via Endogenous Signaling

Linda C. Hsi1,3, Suman Kundu1, Juan Palomo2, Bo Xu1, Ryan Ficco1, Michael A. Vogelbaum2, and Martha K. Cathcart1,3

Abstract

Glioblastoma multiforme (GBM) is one of the most lethal forms of cancer, with a survival rate of only 13% to 27% within 2 years of diagnosis despite optimal medical treatment. We hypothesize that the presence of a unique IL-13Rα2 decoy receptor prevents GBM apoptosis. This receptor has a high affinity for interleukin-13 (IL-13), binds the cytokine, and competitively inhibits the intracellular signaling cascade initiated by IL-13. In cells lacking the IL-13Rα2 decoy receptor, IL-13 initiates the production of 15-lipoxygenase-1 (15-LOX-1), which has been implicated in cellular apoptosis. Our group and others have shown that induction of 15-LOX-1 correlates with tumor cell death in colorectal, pancreatic, and prostate cancer. How 15-LOX-1 induces apoptosis remains unclear. Preliminary evidence in GBM cells implicates an apoptotic process mediated by PPARγ. 15-LOX-1 metabolites can modulate PPARγ and activation of PPARγ can suppress tumor growth. We hypothesize that in GBM, IL-13 can induce 15-LOX-1, which regulates cell apoptosis via signaling through PPARγ and that expression of IL-13Rα2 prevents apoptosis and contributes to tumor growth. Our in vitro and in vivo data support this. Knocking down IL-13Rα2 with short interfering RNA dramatically induces 15-LOX-1 expression, promotes apoptosis, and reduces GBM tumor growth in vivo. These findings identify a mechanism for eliminating the blockade of endogenous IL-13 signaling and for promotion of apoptosis, and characterize a role for 15-LOX-1 in GBM apoptosis. Identifying a mechanistic pathway that can be targeted for pharmacologic intervention will have applied implications to developing novel and effective treatments of GBM. Mol Cancer Ther; 10(7); 1–12. ©2011 AACR.

Introduction

Glioblastoma multiforme (GBM) is the most common malignant brain tumor in adults and one of the most lethal forms of cancer. Studies report that the overall survival of patients with newly diagnosed GBM is 13% to 27% within 2 years of diagnosis, despite optimal medical treatment [i.e., surgery, radiotherapy, and temozolomide; refs. 1, 2]. Poor long-term survival is due to local infiltrative growth within the brain that makes complete surgical resection virtually impossible, the intrinsic radio- and chemotherapeutic resistance of glioma cells, and their high rate of mutation (2, 3). It has been suggested that reducing various signaling pathways such as phosphoinositide 3-kinase (PI3K), Akt, mTOR, or NF-κB may not only reduce tumor growth but also reduce the migratory abilities of glioma cells to restore proapoptotic drug sensitivity to current chemotherapies (4). Within the last few years, the introduction of the oral methylator temozolomide has greatly enhanced the treatment of high-grade gliomas when used in combination with surgery and radiotherapy (2). Nevertheless, less than 10% of patients remain alive 5 years postdiagnosis. This dismal prognosis compares unfavorably with other cancers such as breast, colon, lung, and prostate cancer. New treatments of GBM are urgently needed. Many alternative approaches such as gene therapies, vaccination/immunotherapies, and direct toxin injections are in various stages of preclinical and clinical development (5–7). There is great need for investigations into novel treatment options for this deadly disease.

Recently, several different approaches have been explored in an attempt to increase survival from GBM. Proapoptotic gene therapy approaches, with targets such as TNFα, FasL, and tumor necrosis factor–related apoptosis-inducing ligand (TRAIL) have been proposed; however, these approaches have shown increased neurotoxicity due to nonspecific killing of nontumoral brain cells (6). Other approaches, such as Ad-p53, which target a majority of all tumor cells, have not been successful because of lack of efficacious transduction of a large percentage of cells (8). Several vaccination approaches
have been tested in preclinical and early-phase clinical trials (9, 10). Vaccination approaches will require testing in large phase III trials before conclusive evidence of their clinical effectiveness can be provided (10). Another approach has been the targeting of receptors exclusively expressed on glioma cells with cytotoxic proteins. This approach has had clinical toxicity that is likely because of binding of the toxin to immune cells bearing the physiologic receptor (11, 12).

GBM expresses interleukin-13 (IL-13) receptors (13, 14). IL-13 is a proinflammatory, Th-2–derived cytokine that is known to induce apoptosis in many different cell types, including GBM cells (15, 16); however, even in the presence of endogenous or artificially elevated IL-13, GBM cells maintain a very low level of apoptosis. One emerging explanation for this phenomenon is the presence of an IL-13Rα2 receptor subunit by GBM. IL-13Rα2 is overexpressed in a variety of human tumors, and previous studies have shown that it can serve as a biomarker of disease and a target for cancer therapy (17). IL-13 plays a central role in inflammation and immune responses and binds to 2 receptor subunits, IL-13Rα1 and IL-13Rα2 (18). IL-13Rα1 is a ubiquitously expressed low-affinity IL-13, but after binding to IL-13, it recruits IL-4Rα and forms a high-affinity IL-13R complex (type II IL-13R) and mediates signal transduction through the Janus-activated kinase (JAK)-STAT pathway (19, 20). IL-13Rα2, on the other hand, binds IL-13 with extremely high affinity and internalizes, but it does not mediate signal transduction (21). It has been hypothesized that the extracellular domain of IL-13Rα2 may serve as a decoy receptor for the type II IL-13R complex (22, 23).

GBM has high levels of IL-13Rα2 receptor present compared with normal tissue. For example, approximately 80% glioblastoma tumors express high levels of IL-13Rα2 whereas corresponding normal brain tissues do not show detectable levels of this receptor (14). IL-13Rα1 is a normal receptor for IL-13 and, once bound, initiates a signaling cascade that culminates in the transcription of several different genes. One of the resulting proteins is 15-lipoxygenase-1 (15-LOX-1), an enzyme that can oxidize esterified or free fatty acids and that can promote apoptosis (24–26). For example, 15-LOX-1 has been shown to play important roles in colorectal carcinogenesis (27–29). Restoring 15-LOX-1 expression by various means has been shown to restore and be mechanistically linked to apoptosis in colorectal cancer cells (24, 25, 29). We hypothesized that induction of 15-LOX-1 may also promote apoptosis in GBM; however, in GBM, the presence of IL-13Rα2 acts like a decoy receptor and does not allow normal IL-13 signaling to occur.

15-LOX-1 catalyzes the oxidization of arachidonic acid and linoleic acid (LA) into 15-(S)-hydroperoxyeicosatetraenoic acid and 13-(S)-hydroperoxide octadecadienoic acid (13-HpODE), respectively. Interestingly, these are the metabolic precursors to 15-(S)-hydroxyeicosatetraenoic acid and 13-(S)-hydroxy-octadecadienoic acid, both of which are known to activate the ligand-dependent nuclear receptor PPARγ. Recently, PPARγ has emerged as a potential player in the IL-13–induced apoptosis pathway (30). The mechanism by which PPARγ inhibits proliferation varies greatly among cell types and is not fully understood in GBM cells (31, 32); however, it does seem that some PPARγ ligands can induce apoptosis in GBM cells (32, 33).

Toxins have been designed to target the IL-13 receptor, which generally would bind to all IL-13 receptors and are meant to be toxic to the cells bearing IL-13 receptors. One such agent is IL13-PE38QQR, the recombinant cytotoxin composed of IL-13 and a truncated form of Pseudomonas aeruginosa exotoxin A. This approach was tested preclinically and in phase I–III clinical trials (7). Although there were high expectations for this approach, the phase III trial failed to achieve clinical endpoints. Reasons for failure are likely to have been the short half-life of IL13-PE38QQR, clinical toxicity that limited the doses that could safely be delivered to patients, and little control over toxin administration. The clinical toxicity was likely because of binding of the toxin to the physiologic IL-13Rα1/IL-4α type II receptor. This toxin would be predicted to be harmful for normal immune cells bearing the IL-13Rα1 receptor.

Rather than pursuing the targeting of the IL-13Rα2 receptor with a toxin or blocking IL-13 interaction with its receptors, we have taken an alternative approach to specifically inhibit expression of IL-13Rα2 in glioma cells by using short interfering RNA (siRNA). The siRNA does not inhibit the expression of the physiologic IL-13Rα1/IL-4α receptor. With this novel approach, by specifically targeting and silencing the IL-13Rα2 receptor only, we now allow normal endogenous IL-13 signaling cascades to proceed, which can then initiate apoptotic pathways leading to GBM tumor cell death. We hypothesize that an siRNA targeted to IL-13Rα2 will effectively and specifically eliminate IL-13Rα2-expressing GBM cells with reduced neurotoxicity and off-target effects.

Materials and Methods

Cell culture

U87 and A172 cells (obtained from the American Type Culture Collection) were grown at 37°C in a humidified 5% CO2/95% air atmosphere. Cells were passaged within 6 months of receiving the cell lines from the established cell bank. The cancer cells were authenticated by their ability to form cancer tumors in athymic nude mice. The cells were tested to be Mycoplasma free by PCR methods before this study. The culture medium for U87 cells was Eagle’s Minimal Essential Medium (EMEM; 1×; Life Technologies) with Earle’s salts supplemented with 10% FBS, sodium pyruvate, nonessential amino acids (Invitrogen), penicillin, and streptomycin. The culture medium for A172 cells was Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 10% FBS, l-glutamine, penicillin, and streptomycin. Trypsin
(Life Technologies) was used to subculture cells. Unless otherwise specified, all chemicals and reagents were from Sigma.

**Treatment with IL-13**

Treatment groups were compared with vehicle controls. Treatment with IL-13 (BioSource) was done at the dose and for the times indicated. Dose and time ranges were selected on the basis of previous reports utilizing this compound (34).

**RNA interference**

Smartpool siGENOME siRNA reagents for IL-13Ra2 siRNA were obtained from Dharmacon and handled according to the manufacturer’s instructions. Transfection of siRNA was carried out using Lipofectamine 2000 (Invitrogen) according to the manufacturer’s specifications. Control cells were similarly transfected without siRNAs (i.e., vehicle only). Untreated cells, mock transfected cells, and transfection of nontarget siRNA were used as controls. Nontarget siRNAs were obtained from Dharmacon. After transfection, cells were replenished with regular medium for various time periods. Cells were assayed for silencing 24, 48, and 72 hours after transfection. Treatment groups were compared with vehicle controls.

**Western blot analysis of 15-LOX-1, PPARγ, and IL-13Ra2 protein**

Following appropriate treatment protocols, we analyzed cell lysates for 15-LOX-1, PPARγ, and IL-13Ra2 levels. Cells were lysed in lysis buffer containing protease and phosphatase inhibitors. Protein concentration was measured by Bradford’s method. Western blot analysis was conducted using standard Western blotting techniques, with specific antibodies directed against human cellular proteins. 15-LOX-1, PPARγ, and IL-13Ra2 Western blot analysis was conducted using a 15-LOX-1 primary antibody (1:1,000; antibody supplied by J. Cornicelli), a PPARγ primary antibody (Santa Cruz Biotechnology SC-7273) at a dilution of 1:2,000, and an IL-13Ra2 primary antibody (Cayman Chemical) was used for treatment. Cells were pretreated with the PPARγ antagonist GW9662 (5 μmol/L; BioSource), rosiglitazone (5 μmol/L; Cayman Chemical), or troglitazone (5 μmol/L; Cayman Chemical) was used for treatment. Cells were treated from 0 (control) to 96 hours as noted. Cells were pretreated with the PPARγ antagonist GW9662 (5 μmol/L; Cayman) for 30 minutes before any additional treatment. Dose and time ranges were selected on the basis of previous reports utilizing these compounds (36). Each assay was carried out in at least 3 independent experiments.

**Real-time PCR analysis**

The real-time PCR (RT-PCR) conditions, primers, and sequences for 15-LOX-1 were done as described previously (35). PCR products were resolved on 2% agarose gels.

**Measurement of IL-13**

IL-13 was measured using the Quantikine Human IL-13 Kit (R&D Systems) according to the manufacturer’s specifications. All samples were assayed in duplicate. Each assay was carried out in at least 2 independent experiments.

**Cellular apoptosis**

Independent methods were used to measure apoptosis. Apoptosis was measured by ELISA Cell Death Detection Kit (Roche), which detects mono- and oligonucleosomes in the cytoplasmic fraction of cell lysates, according to the manufacturer’s specifications. Each assay was carried out in at least 3 independent experiments. Annexin V/propidium iodide (PI) staining was done, followed by FACScan flow cytometry. Equal numbers of cells (1 × 10⁶) were plated onto 6-well dishes and then following treatment of interest, cells were washed twice in PBS and then resuspended in Annexin V binding buffer containing 2 μL Annexin V–fluorescein isothiocyanate and 10 μL PI. After incubation in the dark at room temperature for 15 minutes, the cells were immediately analyzed by FACScan flow cytometry. For statistical analysis, Student's t test was used to determine the statistical differences between various experimental and control groups. Data were reported as the mean ± SD. A value of P < 0.05 was considered significant.

**Treatment with IL-13, PPARγ agonists, or PPARγ antagonists**

Treatment groups were compared with vehicle controls. IL-13 (50 μg/mL; BioSource), rosiglitazone (5 μmol/L; Cayman Chemical), or troglitazone (5 μmol/L; Cayman Chemical) was used for treatment. Cells were treated from 0 (control) to 96 hours as noted. Cells were pretreated with the PPARγ antagonist GW9662 (5 μmol/L; Cayman) for 30 minutes before any additional treatment. Dose and time ranges were selected on the basis of previous reports utilizing these compounds (36). Each assay was carried out in at least 3 independent experiments.

**Tumorigenesis in nude mice**

U87 cells were harvested, counted, and suspended in an equal volume of Matrigel. A total of 2.5 × 10⁶ cells in 500 μL Matrigel were injected under the dorsal skin of
nude mice. For uniform development of visible tumors, the animals were left for 2 weeks without any treatment. Ten mice were used in each group. Tumor volume was measured beginning from week 2, using a digital vernier caliper. Tumor volume was calculated using the formula \[ \text{tumor volume} = \frac{1}{2} \times (\text{smallest diameter} \times \text{widest diameter}) \], and the growth curves were plotted for each group. Starting tumor volume ranges for each group were as follows: control, 143–380 mm³; nontarget siRNA, 198–353 mm³; IL-13Rα2 5 μmol/L siRNA, 151–309 mm³; IL-13Rα2 10 μmol/L siRNA, 158–341 mm³. The mice were then injected at the tumor site with IL-13Rα2 siRNA (5 or 10 μmol/L), nontarget siRNA (10 μmol/L), or vehicle alone twice per week for 4 weeks. The siRNA plasmid vector was mixed with in vivo-jetPEI (Ployplus-transfection) in 5% glucose solution (100 μL per injection). siRNA was infused at a rate of 20 μL/min and the needle was left in place for 1 minute postinjection before removal to prevent backflow. Animals were assessed visually every day thereafter. Tumor volume measurements were taken before each injection. At the end of the fourth week, the tumors were measured and the animals were sacrificed and photographed. The tumors were surgically removed, weighed, and photographed. All animal experiments were approved by and in compliance with our Institutional Animal Care and Use Committee. Animals exhibiting abnormal behavior (e.g., hair loss, jerking movements, hemiparesis, loss of grooming behavior) or evidence of pain or distress was euthanized according to approved protocols. Animals with ulcerated tumors and 100% of the IL-13Rα2 mRNA in a dose-dependent manner. By RT-PCR, 5 and 10 nmol/L IL-13Rα2 siRNA inhibited approximately 65% and 80% of the IL-13Rα2 mRNA, respectively (Fig. 1A). As a control, the effect of IL-13Rα2 siRNA on glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was examined. The IL-13Rα2 siRNA did not have an effect on GAPDH mRNA production. The IL-13Rα2 protein expression was also significantly downregulated by treatment with IL-13Rα2 siRNA at both 48 and 72 hours (Fig. 1B).

IL-13Rα2 siRNA treatment induces apoptosis in GBM cells

To determine whether IL-13Rα2 blocks GBM apoptosis, we treated A172 cells with IL-13Rα2 siRNA (5 nmol/L) for 48 and 72 hours. Apoptosis was assessed by Annexin V/PI staining, followed by FACSscan flow cytometry. Treatment with IL-13Rα2 siRNA (5 nmol/L) induced apoptosis in a time-dependent manner, with 25% and 65% cell death at 48 and 72 hours, respectively (Fig. 2A). Treatment with the PPARγ antagonist GW9662 (5 μmol/L) reduced this effect, suggesting the involvement of PPARγ in GBM apoptosis. Control cells, cells treated with GW9662 alone, oligofectamine, or nontarget siRNA controls did not have increased apoptosis.

Treatment with IL-13Rα2 siRNA promotes 15-LOX-1 expression in GBM cells

The production of 15-LOX-1, an enzyme whose production has been previously linked to the IL-13 signaling cascade through the type II receptor (34) and is known to catalyze the production of PPARγ-specific ligands
and apoptosis, was examined next. To explore this, the IL-13Rα2 decoy receptor was inhibited using IL-13Rα2 siRNA. RT-PCR was used to determine the effects of siRNA on the production of 15-LOX-1 mRNA levels. Inhibition of IL-13Rα2 by 5 and 10 nmol/L IL-13Rα2 siRNA increased the production of 15-LOX-1 20- and 30-fold, respectively (Fig. 2B). This is particularly interesting because the cells were not exposed to any
exogenous IL-13, the usual inducer of 15-LOX-1 expression. The upregulation of 15-LOX-1 suggests that the cells are releasing IL-13 endogenously. We have confirmed the presence of IL-13 in the GBM cell supernatant by ELISA (data not shown). We have found greater than 2.5-fold higher levels of IL-13 in IL-13Rα2 siRNA treated cells than in control cells. 15-LOX-1 protein was also significantly upregulated by treatment with IL-13Rα2 siRNA (Fig. 2C).

**PPARγ is expressed in GBM cells and PPARγ ligands induce apoptosis in GBM cells**

To determine whether PPARγ is present in GBM cells, PPARγ expression in A172 cells was examined by Western analysis. PPARγ is expressed in A172 cells (Fig. 3A). To establish PPARγ function in the apoptotic process, the PPARγ ligand troglitizone or rosiglitizone was tested to determine whether they could induce apoptosis in GBM cells and whether the PPARγ antagonist GW9662 could alter this effect. A172 cells were treated for 24 to 72 hours, and apoptosis was assessed by Annexin V/PI staining, followed by FACSscan flow cytometry. Both PPARγ ligands induced apoptosis in a time-dependent manner (>60% total cell death by 72 hours) in A172 cells and treatment with GW9662 (5 μmol/L) significantly reduced this effect (Fig. 3B). Control cells or cells treated with GW9662 alone or IL-13 did not have increased apoptosis.

**13-HpODE, the 15-LOX-1 metabolite, induces apoptosis in GBM cells**

To determine whether the 15-LOX-1 metabolite 13-HpODE can induce apoptosis in GBM cells, we treated A172 cells with 13-HpODE and assessed apoptosis. Cells were treated with 13-HpODE for 4 hours and then microscopically examined to identify morphologic changes associated with apoptosis (Fig. 4A). Cells treated with 13-HpODE were clearly altered, with morphologic changes that indicate apoptosis, including cytoplasmic and nuclear shrinkage. Cells were also treated with LA, the substrate for 15-LOX-1, which is metabolized to 13-HpODE. Cells treated with LA were not affected. Control cells and vehicle-treated cells were also not affected. After 24 hours of treatment, apoptosis of the A172 cells was measured by ELISA cell death detection (Fig. 4B). Cells treated with 13-HpODE underwent apoptosis, whereas control cells, vehicle-treated cells, and LA treated cells were not affected. Apoptosis was also confirmed by Annexin V/PI staining, followed by FACSscan flow cytometry (Fig. 4C). A172 cells were treated with IL-13, LA, or 13-HpODE for 48 and 72 hours. Apoptosis occurred with 13-HpODE treatment but not with the other treatments. Pretreatment with the PPARγ antagonist GW9662 for 30 minutes attenuated the 13-HpODE-induced apoptosis.

**Treatment with IL-13Rα2 siRNA promotes 15-LOX-1 expression in U87 GBM cells**

We next examined the production of 15-LOX-1 in U87 cells. We were interested in the U87 cell line for 2 reasons. First, it is important to confirm our findings in different glioblastoma cell lines for validity. Second, the U87 cell line has previously been shown to grow well in both heterotopic and orthotopic in vivo GBM models, whereas the A172 cell line has been shown to grow well only in a heterotopic in vivo GBM model. (M.A. Vogelbaum, personal communication). Thus, it is important to confirm our results in a cell line such as U87 to move forward with orthotopic in vivo studies. It is vital to be able to extend our studies to an orthotopic GBM model system because of the potential impact of a functional blood–brain barrier and other local environment factors that may be present in the brain. To explore the effects in U87 cells, the IL-13Rα2 decoy receptor was inhibited using IL-13Rα2 siRNA. Inhibition of IL-13Rα2 by 5 nmol/L IL-13Rα2 siRNA increased the production of 15-LOX-1 protein in U87 cells (Fig. 5A).

**IL-13Rα2 siRNA treatment induces apoptosis in U87 GBM cells**

To determine whether IL-13Rα2 blocks IL-13-induced apoptosis in U87 cells, we treated U87 cells...
with IL-13Rα2 siRNA (5 nmol/L) for 72 hours. Apoptosis was assessed by Annexin V/PI staining, followed by FACScan flow cytometry. Treatment with IL-13Rα2 siRNA (5 nmol/L) induced apoptosis, with 30% cell death at 72 hours (Fig. 5B). Treatment with GW9662 (5 μmol/L), the PPARγ antagonist, reduced this effect. Control cells, cells treated with GW9662 alone, Lipofectamine, or nontarget siRNA controls did not have increased apoptosis.

To establish PPARγ function, we tested whether the PPARγ ligand rosiglitizone could induce apoptosis in U87 cells and whether GW9662 (GW; 5 μmol/L), a PPARγ antagonist, was done for 30 minutes. Apoptosis was assessed by Annexin V/PI staining, followed by FACScan flow cytometry. The data shown represent 1 of 3 separate experiments giving similar results.

**IL-13Rα2 siRNA treatment in vivo reduces GBM tumor growth**

To determine whether IL-13Rα2 siRNA can inhibit tumor growth in vivo, we injected U87 GBM cells into the flank of athymic mice. Because A172 cells grow very slowly to form a subcutaneous solid tumor, we used U87 cells to study subcutaneous solid tumor development. We injected a U87 cell suspension in Matrigel under the dorsal skin of nude mice. The animals were left for 2 weeks without any treatment for the development of visible and palpable tumors. Animals were then divided into 4 groups of 10 mice each. Tumor volume was measured beginning from week 2. Intratumoral injections with IL-13Rα2 siRNA (5 or 10 nmol/L), nontarget control (NTC) siRNA, or vehicle were done 2 times per week for 4 weeks. Tumor volume was measured before each injection. After the fourth week, animals were photographed (Fig. 6A) and sacrificed, tumors were measured (Fig. 6B), and then...
surgically removed, photographed (Fig. 6C), and weighed (Fig. 6D). Inhibition of IL-13Rα2 siRNA (31%) and IL-13Rα2 siRNA (5 nmol/L) or rosiglitizone (Rosi; 5 μmol/L), and apoptosis was assessed at 72 hours. Pretreatment with GW9662 (GW; 5 μmol/L), a PPARγ antagonist, was done for 30 minutes. Apoptosis was assessed by Annexin V/PI staining, followed by FACScan flow cytometry. The data shown represent 1 of 3 separate experiments giving similar results.

Discussion

Our data suggest that the unique expression of an IL-13Rα2 decoy receptor in GBM prevents IL-13 from initiating an intracellular cascade that can lead to apoptosis of GBM cells and thereby contributes to tumor growth. We show for the first time that the down-regulation of the expression of this decoy receptor allows induction of 15-LOX-1-mediated cell death. From our studies, we establish a molecular mechanism and confirm a role for 15-LOX-1 in apoptosis in GBM cells. We show that when the expression of the IL-13 decoy receptor is inhibited, 15-LOX-1 is induced in GBM, which, in turn, can generate metabolites such as 13-HpODE, which can activate PPARγ and lead to apoptosis. This mechanism provides an explanation for how the expression of the decoy receptor IL-13Rα2 may prevent GBM apoptosis and contribute to tumor growth (Fig. 7). Thus, we have identified both a novel approach and a pathway for inducing apoptosis in GBM cells and perhaps for therapeutic treatment of GBM.

The utilization of RNA interference (RNAi) has been a major breakthrough in cellular biology. RNAi has become the technique of choice for the analysis of gene function and created the possibility for therapeutic gene silencing for cancer treatment, especially for drug-resistant cancers (39). RNAi is potent, as only a few siRNA molecules per cell are required to produce effective gene silencing (40, 41). In the case of GBM, IL-13Rα2 may serve as an important therapeutic siRNA target, as it is highly expressed in gliomas but not in normal brain. The advantage of using IL-13Rα2 siRNA to specifically silence the receptor compared with other IL-13–based treatment strategies is that we specifically knock down the IL-13Rα2 receptor and do not target functional IL-13 receptors more generally as other current treatments have done and take advantage of an endogenous signaling pathway involving 15-LOX-1 that leads to glioma cell apoptosis and tumor inhibition. For example, the recombinant cytotoxin composed of IL-13 and a truncated form of *P. aeruginosa* exotoxin A (IL13-Pe38QQR) targets both IL-13 receptors (7). We believe that the IL-13Rα1 receptor is needed to allow normal endogenous signaling mechanisms to occur, which can ultimately lead to cell death of GBM cells.

Although IL-13Rα2 has been shown to be overexpressed on certain types of human cancer, including glioblastoma, head and neck cancer, kidney cancer, ovarian cancer, medulloblastoma, and Kaposi’s sarcoma (42), its role in signal transduction in cancer is unknown. By specifically targeting and silencing the IL-13Rα2 receptor only, we now allow endogenous signaling through 15-LOX-1 to occur, which can then lead to GBM tumor cell death. This is particularly promising, given that fact that new treatments are urgently needed for this deadly disease. Use of IL-13Rα2 siRNA is a novel approach and could be an effective treatment option for GBM with minimal side effects.
effects, as we are now allowing normal endogenous signaling cascades to initiate.

Further investigations are needed to advance the implementation of this novel therapeutic approach. Although initial studies using the *in vivo* flank model are promising, many heterotopic GBM models, such as the mouse flank tumor model, do not take into account the impact of a functional blood–brain barrier and other local environment factors that may be present in the brain. Use of an intracranial GBM model will allow us to take into account the different environments found in the brain. In our flank model studies, we observed continued tumor growth despite administration of the IL-13Rα2 siRNA. This effect may be due to inadequate dosing and/or delivery of the IL-13Rα2 siRNA.

Because of the nature of direct injections, there is potential difficulty in obtaining uniform delivery of siRNA to all tumor tissues. The distribution of the siRNA can be affected by several factors: needle placement into the tumor, needle-induced tissue damage, tumor tissue structure, infusion rate of the siRNA, and prevention of backflow. These challenges have limited the progress of drug/agent delivery in the clinical setting and have pointed to the need to refine and develop new delivery methods.

The next challenges are to validate our findings in orthotopic models and to optimize dosing and delivery. Both *in vivo* animal studies and subsequent clinical trials require an effective mode of delivery for siRNA therapy such as IL-13Rα2 siRNA. siRNA has a
large enough molecular weight that it is unlikely to cross the blood–brain barrier following intravenous injection without a delivery system. Direct administration can be an effective method to deliver macromolecules to the brain parenchyma; however, as discussed, with direct administration, there is potential difficulty in obtaining uniform delivery to all tumor tissue. Currently, chemotherapeutic drug-impregnated biodegradable wafers and bolus injection rely upon simple diffusion to drive the drug into the brain parenchyma (43, 44). Convection-enhanced delivery (CED) supplements diffusion and allows effective delivery of therapeutic agents at a relatively uniform concentration (44, 45). This technique uses positive pressure to generate a continuous pressure gradient over a given time period. The trials of IL13-PE38QQR delivered by CED in the setting of newly diagnosed and recurrent GBM provide proof of principle that a targeted macromolecule can be delivered. CED provides homogenous, clinically significant, reproducible delivery of macromolecules into the brain parenchyma. This method of delivery may also be suitable for siRNA-targeted therapy.

Other methods of RNAi delivery that facilitate delivery of therapeutically significant quantities of RNA to the central nervous system via the systemic route have been explored. One approach has used liposomes constructed with antibodies to recognize 2 specific proteins (46). One antibody that is engineered into the liposomes recognizes only the transferrin receptor, a protein common to the blood–brain barrier. By binding the transferring receptor, the liposomes gain entry to the compartment that houses and protects the brain. Once inside the compartment, a second liposome-embedded antibody binds to the human insulin receptor found in the membranes of brain cancer cells. Now within the tumor cell, the liposomes release the plasmid they carry that encodes a short hairpin RNA designed to interfere with the expression of epidermal growth factor receptor (EGFR), a proponent of tumor cell proliferation. Without EGFR to encourage cell proliferation, the tumor growth is held in check. Preclinical studies on mice by using this approach have shown encouraging results (46). Another transvascular method to deliver siRNA across the blood–brain barrier to the brain via intravenous injection has been explored. This method involves complexing siRNA to a short peptide derived from the rabies virus glycoprotein that binds specifically to acetylcholine receptors on neuronal cells (47, 48) and encapsulating the siRNA with liposomes to protect the siRNA from degradation and improve delivery through the vasculature. Use of antibodies or peptides with liposomes to traverse both the blood–brain barrier and the tumor cell membrane may prove to be an
effective means of delivering IL-13Rα2 RNAi for the treatment of GBM.

Another approach for siRNA delivery that has recently been examined is the use of a multistage vector composed of mesoporous silicon particles (stage 1 microparticles) loaded with neutral nanoliposomes [dioleoyl phosphatidylcholine (DOPC)] containing siRNA targeted against the EphA2 oncoprotein, which is overexpressed in most cancers, including ovarian (49). This delivery method resulted in sustained EphA2 gene silencing for at least 3 weeks following a single intravenous administration of stage 1 microparticles loaded with EphA2-siRNA-DOPC. Furthermore, tumor burden, angiogenesis, and cell proliferation were substantially reduced compared with a noncoding control siRNA alone (49). This novel, multistage siRNA delivery system for sustained gene silencing may have broad applicability to pathologies beyond ovarian neoplasms and perhaps may be useful for the treatment of GBM.

The effects of silencing the IL-13Rα2 receptor with IL-13Rα2 siRNA on 15-LOX-1 expression and apoptosis in our study support the potential promise of siRNA-directed targeting for GBM therapy. Although we are optimistic about the potential of siRNA-directed targeting to IL-13Rα2, we must also keep in mind the possibility of combining this approach with other established therapies to further enhance therapeutic effects. Given the polygenetic nature of GBM, the efficacy and specificity of GBM treatment will likely be further enhanced by using a combination approach of siRNA with another traditional therapy such as chemotherapy, radiotherapy, or immunotherapy. Recently, combinatorial approaches have been explored and shown to be successful for improving efficacy of the treatment of GBM. For example, the combination of temozolomide with surgery and radiotherapy has greatly enhanced the treatment of high-grade gliomas (2, 50). In the future, IL-13Rα2 siRNA should be explored as a tantalizing new approach to be used in combination with other agents to improve the efficacy of GBM treatment.

Disclosure of Potential Conflict of Interest

No potential conflicts of interest were disclosed.

Acknowledgments

The authors thank the staff of the Flow Core Facility and the Center for Medical Art & Photography for providing technical assistance.

Grant Support

This research was supported in part by grant ACSODSR2009-2 from the American Cancer Society (L.C. Hsi) and PO1-HL087018 from the NIH (M.K. Cathcart).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received November 23, 2010; revised March 11, 2011; accepted May 13, 2011; published OnlineFirst May 19, 2011.

References

3. Sanai N, Berger MS. Glioma extent of resection and its impact on targetting to IL-13Rα. We are optimistic about the potential of siRNA-directed targeting for GBM therapy. Although apoptosis in our study support the potential promise with IL-13Rα effects. Given the polygeni cn a t u r eo f G B M , t h e e f f i -
4. Lefranc F, Brotchi J, Kiss R. Possible future issues in the treatment of GBM.


24. Hsi LC, Xi X, Lotan R, Shureiqi I, Lippman SM. The histone deace...


32. Grommes C, Landreth GE, Schlegel U, Heneka MT. The nonhaizol...
Molecular Cancer Therapeutics

Silencing IL-13Rα2 Promotes Glioblastoma Cell Death via Endogenous Signaling

Linda C. Hsi, Suman Kundu, Juan Palomo, et al.

Mol Cancer Ther  Published OnlineFirst May 19, 2011.

Updated version  Access the most recent version of this article at:
doi:10.1158/1535-7163.MCT-10-1064